

Hyo Song Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2694394/publications.pdf>

Version: 2024-02-01

95
papers

2,433
citations

172457

29
h-index

243625

44
g-index

96
all docs

96
docs citations

96
times ranked

4554
citing authors

#	ARTICLE	IF	CITATIONS
1	Recommendations for the Use of Next-Generation Sequencing and the Molecular Tumor Board for Patients with Advanced Cancer: A Report from KSMO and KCSG Precision Medicine Networking Group. <i>Cancer Research and Treatment</i> , 2022, 54, 1-9.	3.0	9
2	Phase II Clinical Trial of Eribulin+Gemcitabine Combination Therapy in Previously Treated Patients With Advanced Liposarcoma or Leiomyosarcoma. <i>Clinical Cancer Research</i> , 2022, 28, 3225-3234.	7.0	5
3	PD-L1 expression and overall survival in Asian and western patients with gastric cancer. <i>Future Oncology</i> , 2022, 18, 2623-2634.	2.4	2
4	PD-L1 tumour expression is predictive of pazopanib response in soft tissue sarcoma. <i>BMC Cancer</i> , 2021, 21, 336.	2.6	4
5	Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β -catenin immunohistochemical staining and CTNNB1 mutation analysis. <i>PLoS ONE</i> , 2021, 16, e0250619.	2.5	8
6	Detection of asymptomatic recurrence improves survival of gastric cancer patients. <i>Cancer Medicine</i> , 2021, 10, 3249-3260.	2.8	10
7	Prognostic implications of PD-L1 expression in patients with angiosarcoma. <i>Future Science OA</i> , 2021, 7, FSO691.	1.9	4
8	Pemetrexed plus cisplatin in patients with previously treated advanced sarcoma: a multicenter, single-arm, phase II trial. <i>ESMO Open</i> , 2021, 6, 100249.	4.5	3
9	Comprehensive Immuno-Molecular Profiles for Liposarcoma: Roles of Programmed Death Ligand 1, Microsatellite Instability, and PIK3CA. <i>Oncology</i> , 2020, 98, 817-826.	1.9	4
10	Phase 2 study of afatinib among patients with recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Cancer</i> , 2020, 126, 4521-4531.	4.1	10
11	Real-World Outcomes of Pazopanib Treatment in Korean Patients with Advanced Soft Tissue Sarcoma: A Multicenter Retrospective Cohort Study. <i>Targeted Oncology</i> , 2020, 15, 485-493.	3.6	6
12	Phase II trial of preoperative sequential chemotherapy followed by chemoradiotherapy for high-risk gastric cancer. <i>Radiotherapy and Oncology</i> , 2019, 140, 143-149.	0.6	7
13	S-1 Based Doublet as an Adjuvant Chemotherapy for Curatively Resected Stage III Gastric Cancer: Results from the Randomized Phase III POST Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 1-11.	3.0	17
14	Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer. <i>European Journal of Cancer</i> , 2019, 112, 20-28.	2.8	2
15	Clinical analysis of patients with skeletal metastasis of lung cancer. <i>BMC Cancer</i> , 2019, 19, 303.	2.6	42
16	Differences in the Efficacies of Pazopanib and Gemcitabine/Docetaxel as Second-Line Treatments for Metastatic Soft Tissue Sarcoma. <i>Oncology</i> , 2019, 96, 59-69.	1.9	14
17	Immunohistochemistry Biomarkers Predict Survival in Stage II/III Gastric Cancer Patients: From a Prospective Clinical Trial. <i>Cancer Research and Treatment</i> , 2019, 51, 819-831.	3.0	10
18	The prognostic value of volume-based parameters using 18F-FDG PET/CT in gastric cancer according to HER2 status. <i>Gastric Cancer</i> , 2018, 21, 213-224.	5.3	32

#	ARTICLE	IF	CITATIONS
19	Multidisciplinary treatment for patients with stage IV gastric cancer: the role of conversion surgery following chemotherapy. <i>BMC Cancer</i> , 2018, 18, 1116.	2.6	51
20	Efficacy of Postoperative Radiotherapy Using Modern Techniques in Patients with Retroperitoneal Soft Tissue Sarcoma. <i>Yonsei Medical Journal</i> , 2018, 59, 1049.	2.2	7
21	A Prediction Model of Tumor Progression and Survival in HER2-Positive Metastatic Gastric Cancer Patients Treated with Trastuzumab and Chemotherapy. <i>AAPS Journal</i> , 2018, 20, 72.	4.4	0
22	Marked Loss of Muscle, Visceral Fat, or Subcutaneous Fat After Gastrectomy Predicts Poor Survival in Advanced Gastric Cancer: Single-Center Study from the CLASSIC Trial. <i>Annals of Surgical Oncology</i> , 2018, 25, 3222-3230.	1.5	69
23	Prognostic implications of polycomb proteins ezh2, suz12, and eed1 and histone modification by H3K27me3 in sarcoma. <i>BMC Cancer</i> , 2018, 18, 158.	2.6	16
24	Prognostic significance of preoperative CT findings in patients with advanced gastric cancer who underwent curative gastrectomy. <i>PLoS ONE</i> , 2018, 13, e0202207.	2.5	5
25	Retrospective analysis of palliative chemotherapy for the patients with bladder adenocarcinoma: Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Korean Journal of Internal Medicine</i> , 2018, 33, 383-390.	1.7	9
26	Patterns of Care for Radiotherapy in the Neoadjuvant and Adjuvant Treatment of Gastric Cancer: A Twelve-Year Nationwide Cohort Study in Korea. <i>Cancer Research and Treatment</i> , 2018, 50, 118-128.	3.0	5
27	Different subtypes of epithelioid sarcoma and their clinical implication: long-term multi-institutional experience with a rare sarcoma. <i>Apmis</i> , 2017, 125, 223-229.	2.0	15
28	Reassessment of alkaline phosphatase as serum tumor marker with high specificity in osteosarcoma. <i>Cancer Medicine</i> , 2017, 6, 1311-1322.	2.8	48
29	Integration of radiotherapy and chemotherapy for abdominal lymph node recurrence in gastric cancer. <i>Clinical and Translational Oncology</i> , 2017, 19, 1268-1275.	2.4	6
30	Outcomes of Treatment for Malignant Peripheral Nerve Sheath Tumors: Different Clinical Features Associated with Neurofibromatosis Type 1. <i>Cancer Research and Treatment</i> , 2017, 49, 717-726.	3.0	32
31	Cardiotoxicity of trastuzumab in patients with HER2-positive gastric cancer. <i>Oncotarget</i> , 2017, 8, 61837-61845.	1.8	16
32	Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab. <i>Oncotarget</i> , 2017, 8, 31169-31179.	1.8	13
33	Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer. <i>Oncotarget</i> , 2017, 8, 38389-38398.	1.8	8
34	Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus. <i>Oncotarget</i> , 2016, 7, 10547-10556.	1.8	52
35	Prognostic Model to Predict Survival Outcome for Curatively Resected Liposarcoma: A Multi-Institutional Experience. <i>Journal of Cancer</i> , 2016, 7, 1174-1180.	2.5	25
36	A Retrospective Analysis for Patients with HER2-Positive Gastric Cancer Who Were Treated with Trastuzumab-Based Chemotherapy: In the Perspectives of Ethnicity and Histology. <i>Cancer Research and Treatment</i> , 2016, 48, 553-560.	3.0	19

#	ARTICLE	IF	CITATIONS
37	Comprehensive expression profiles of gastric cancer molecular subtypes by immunohistochemistry: implications for individualized therapy. <i>Oncotarget</i> , 2016, 7, 44608-44620.	1.8	46
38	Genetic alterations and their clinical implications in gastric cancer peritoneal carcinomatosis revealed by whole-exome sequencing of malignant ascites. <i>Oncotarget</i> , 2016, 7, 8055-8066.	1.8	42
39	Cumulative Metformin Use and Its Impact on Survival in Gastric Cancer Patients After Gastrectomy. <i>Annals of Surgery</i> , 2016, 263, 96-102.	4.2	56
40	Prognostic implications of PD-L1 expression in patients with soft tissue sarcoma. <i>BMC Cancer</i> , 2016, 16, 434.	2.6	124
41	Recursive partition analysis of peritoneal and systemic recurrence in patients with gastric cancer who underwent D2 gastrectomy: Implications for neoadjuvant therapy consideration. <i>Journal of Surgical Oncology</i> , 2016, 114, 859-864.	1.7	13
42	Multidisciplinary treatment of inferior vena cava leiomyosarcoma. <i>ANZ Journal of Surgery</i> , 2016, 86, 104-105.	0.7	1
43	A novel <i>TP53-KPNA3</i> translocation defines a de novo treatment-resistant clone in osteosarcoma. <i>Journal of Physical Education and Sports Management</i> , 2016, 2, a000992.	1.2	13
44	Prognostic significance and frequency of EGFR expression and amplification in surgically resected advanced gastric cancer. <i>Japanese Journal of Clinical Oncology</i> , 2016, 46, 507-516.	1.3	11
45	Prognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with gastric neuroendocrine carcinoma and mixed adenoneuroendocrine carcinoma. <i>Annals of Nuclear Medicine</i> , 2016, 30, 279-286.	2.2	16
46	Receptor tyrosine kinase amplified gastric cancer: Clinicopathologic characteristics and proposed screening algorithm. <i>Oncotarget</i> , 2016, 7, 72099-72112.	1.8	16
47	Prognostic implications of <i>PIK3CA</i> amplification in curatively resected liposarcoma. <i>Oncotarget</i> , 2016, 7, 24549-24558.	1.8	7
48	<i>PIK3CA</i> amplification is associated with poor prognosis among patients with curatively resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2016, 7, 30691-30701.	1.8	28
49	Efficacy and Toxicity of Mammalian Target Rapamycin Inhibitors in Patients with Metastatic Renal Cell Carcinoma with Renal Insufficiency: The Korean Cancer Study Group GU 14-08. <i>Cancer Research and Treatment</i> , 2016, 48, 1286-1292.	3.0	5
50	Current Strategy of Chemotherapy for Bone Tumors. <i>The Journal of the Korean Orthopaedic Association</i> , 2015, 50, 438.	0.1	0
51	The frequency and impact of <i>FGFR1</i> amplification on clinical outcomes in Korean patients with small cell lung cancer. <i>Lung Cancer</i> , 2015, 88, 325-331.	2.0	8
52	Clinicopathological Features and Prognostic Significance of HER2 Expression in Gastric Cancer. <i>Oncology</i> , 2015, 88, 147-156.	1.9	15
53	PTEN Deficiency as a Predictive Biomarker of Resistance to HER2-Targeted Therapy in Advanced Gastric Cancer. <i>Oncology</i> , 2015, 88, 76-85.	1.9	27
54	Efficacy of pazopanib monotherapy in patients who had been heavily pretreated for metastatic soft tissue sarcoma: a retrospective case series. <i>BMC Cancer</i> , 2015, 15, 154.	2.6	58

#	ARTICLE	IF	CITATIONS
55	Leiomyosarcoma: investigation of prognostic factors for risk-stratification model. <i>International Journal of Clinical Oncology</i> , 2015, 20, 1226-1232.	2.2	9
56	Proper Timing of Adjuvant Chemotherapy Affects Survival in Patients with Stage 2 and 3 Gastric Cancer. <i>Annals of Surgical Oncology</i> , 2015, 22, 224-231.	1.5	50
57	Fibroblast growth factor receptor 1 gene amplification is associated with poor survival in patients with resected esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 2562-2572.	1.8	30
58	Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma. <i>Oncotarget</i> , 2015, 6, 44971-44984.	1.8	13
59	Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. <i>Cancer Research and Treatment</i> , 2015, 47, 781-789.	3.0	10
60	Prognostic implications of anaplastic lymphoma kinase gene aberrations in rhabdomyosarcoma; an immunohistochemical and fluorescence in situ hybridisation study. <i>Journal of Clinical Pathology</i> , 2014, 67, 33-39.	2.0	14
61	Vascular Soft-Tissue Sarcomas: A Prognostic Model from a Retrospective Single-Center Study. <i>Oncology</i> , 2014, 86, 329-335.	1.9	0
62	Ifosfamide-induced Fanconi syndrome with diabetes insipidus. <i>Korean Journal of Internal Medicine</i> , 2014, 29, 246.	1.7	18
63	Clinical Features and Treatment of Collecting Duct Carcinoma of the Kidney from the Korean Cancer Study Group Genitourinary and Gynecology Cancer Committee. <i>Cancer Research and Treatment</i> , 2014, 46, 141-147.	3.0	16
64	Randomized controlled trial of standardized education and telemonitoring for pain in outpatients with advanced solid tumors. <i>Supportive Care in Cancer</i> , 2013, 21, 1751-1759.	2.2	38
65	Pharmacogenetic determinants associated with sunitinib-induced toxicity and ethnic difference in Korean metastatic renal cell carcinoma patients. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 825-835.	2.3	57
66	Efficacy and safety of everolimus in Korean patients with metastatic renal cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 72, 853-860.	2.3	5
67	Therapeutic Strategies for Well-differentiated Papillary Mesothelioma of the Peritoneum. <i>Japanese Journal of Clinical Oncology</i> , 2013, 43, 996-1003.	1.3	27
68	A randomized phase II trial of S-1-oxaliplatin versus capecitabine+oxaliplatin in advanced gastric cancer. <i>European Journal of Cancer</i> , 2012, 48, 518-526.	2.8	116
69	The efficacy and toxicity of S-1 and cisplatin as first-line chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2012, 70, 539-546.	2.3	4
70	Weekly Gemcitabine and Docetaxel in Refractory Soft Tissue Sarcoma: A Retrospective Analysis. <i>Cancer Research and Treatment</i> , 2012, 44, 43-49.	3.0	14
71	Salvage chemotherapy of biweekly irinotecan plus S-1 (biweekly IRIS) in previously treated patients with advanced gastric cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 991-999.	2.3	4
72	A Prognostic Model to Predict Clinical Outcome in Gastric Cancer Patients with Bone Metastasis. <i>Oncology</i> , 2011, 80, 142-150.	1.9	36

#	ARTICLE	IF	CITATIONS
73	Sunitinib for Asian Patients with Advanced Renal Cell Carcinoma: A Comparable Efficacy with Different Toxicity Profiles. <i>Oncology</i> , 2011, 80, 395-405.	1.9	48
74	Advanced Detection of Recent Changing Trends in Gastric Cancer Survival: Up-to-date Comparison by Period Analysis. <i>Japanese Journal of Clinical Oncology</i> , 2011, 41, 1344-1350.	1.3	14
75	Definitive chemoradiation therapy with capecitabine in locally advanced pancreatic cancer. <i>Anti-Cancer Drugs</i> , 2010, 21, 107-112.	1.4	6
76	The Clinical Outcome of Chemotherapy-Induced Amenorrhea in Premenopausal Young Patients with Breast Cancer with Long-Term Follow-up. <i>Annals of Surgical Oncology</i> , 2010, 17, 3259-3268.	1.5	43
77	Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter study. <i>BMC Cancer</i> , 2010, 10, 167.	2.6	52
78	Excision repair cross-complementation group 1 (ERCC1) expression in advanced urothelial carcinoma patients receiving cisplatin-based chemotherapy. <i>Apmis</i> , 2010, 118, 941-948.	2.0	41
79	Molecular biomarkers for advanced renal cell carcinoma: Implications for prognosis and therapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2010, 28, 157-163.	1.6	15
80	Novel Sunitinib Strategy in Metastatic Renal Cell Carcinoma on Hemodialysis: Intermittent Dose of Sunitinib after Hemodialysis. <i>Cancer Research and Treatment</i> , 2010, 42, 180.	3.0	10
81	Clinicopathologic Features of Metachronous or Synchronous Gastric Cancer Patients with Three or More Primary Sites. <i>Cancer Research and Treatment</i> , 2010, 42, 217.	3.0	29
82	Comparison of Survival in Advanced Non-Small Cell Lung Cancer Patients in the Pre- and Post-Gefitinib Eras. <i>Oncology</i> , 2009, 76, 239-246.	1.9	18
83	A retrospective analysis of second-line chemotherapy in patients with advanced gastric cancer. <i>BMC Cancer</i> , 2009, 9, 110.	2.6	37
84	Liposarcoma: exploration of clinical prognostic factors for risk based stratification of therapy. <i>BMC Cancer</i> , 2009, 9, 205.	2.6	44
85	Clinical significance of a serum CA15-3 surge and the usefulness of CA15-3 kinetics in monitoring chemotherapy response in patients with metastatic breast cancer. <i>Breast Cancer Research and Treatment</i> , 2009, 118, 89-97.	2.5	35
86	Irinotecan monotherapy as second-line treatment in advanced pancreatic cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 63, 1141-1145.	2.3	58
87	Irinotecan and oxaliplatin combination as the first-line treatment for patients with advanced non-small cell lung cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2009, 64, 917-924.	2.3	5
88	L1 cell adhesion molecule as a predictor for recurrence in pulmonary carcinoids and large-cell neuroendocrine tumors. <i>Apmis</i> , 2009, 117, 140-146.	2.0	14
89	Whole blood Epstein-Barr virus DNA load as a diagnostic and prognostic surrogate: extranodal natural killer/T-cell lymphoma. <i>Leukemia and Lymphoma</i> , 2009, 50, 757-763.	1.3	63
90	Discordance of Molecular Biomarkers Associated with Epidermal Growth Factor Receptor Pathway between Primary Tumors and Lymph Node Metastasis in Non-small Cell Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2009, 4, 809-815.	1.1	145

#	ARTICLE	IF	CITATIONS
91	Treatment Outcomes of Sunitinib Treatment in Advanced Renal Cell Carcinoma Patients: A Single Cancer Center Experience in Korea. <i>Cancer Research and Treatment</i> , 2009, 41, 67.	3.0	63
92	A phase II study of capecitabine and cisplatin (XP) as first-line chemotherapy in patients with advanced esophageal squamous cell carcinoma. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 62, 77-84.	2.3	38
93	Clinical Outcome of Gastric Cancer Patients with Bone Marrow Metastases. <i>Oncology</i> , 2007, 73, 192-197.	1.9	82
94	Catecholamine Cardiomyopathy Associated With Paraganglioma Rescued by Percutaneous Cardiopulmonary Support Inverted Takotsubo Contractile Pattern. <i>Circulation Journal</i> , 2007, 71, 1993-1995.	1.6	29
95	Incidence and Survival of Pediatric Soft Tissue Sarcomas: Comparison between Adults and Children. <i>Cancer Research and Treatment</i> , 1970, 47, 9-17.	3.0	12